Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, By Product Type (Gene Products, Vaccines, Stem Cells, Monoclonal Antibodies, Others), Service Type (Manufacturing, Research and Development, Clinical Trials, Others), End-Users (Biotechnology Companies, Biopharmaceutical Companies, Others) – Industry Trends and Forecast to 2031.
Biologics Contract Development and Manufacturing Organization (CDMO) Market Analysis and Size
Factors such as increasing cases of spinal fusion surgeries coupled with a rising geriatric population across the globe, have helped in driving the market growth. Rising healthcare expenditure, developments in innovation for new product launches are expected to lavish the growth of the market.
Data Bridge Market Research analyses that the global biologics contract development and manufacturing organization (CDMO) market which was USD 14,971.57 million in 2023, would reach up to USD 34,378.10 million by 2031, and is expected to undergo a CAGR of 11.0% during the forecast period. The “biotechnology companies” in the end-users segment are expected to dominate the market due to higher biological research and development by these companies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Gene Products, Vaccines, Stem Cells, Monoclonal Antibodies, Others), Service Type (Manufacturing, Research and Development, Clinical Trials, Others), End-Users (Biotechnology Companies, Biopharmaceutical Companies, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Boehringer Ingelheim Group (Germany), Wuxi Biologics (China), Samsung Biologics (South Korea), Lonza Group (Switzerland), Fujifilm Diosynth Biotechnologies USA Inc. (U.S.), Toyobo Co. Limited (Japan), Parexel International Corporation (U.S.), Icon PLC (Ireland), Binex Co. Limited (South Korea), JRS Pharma (Germany), Rentschler Biotechnologies (Germany), AGC Biologics (U.S.), Catalent Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
A Biologics CDMO (Contract Development and Manufacturing Organization) is a specialized company that offers services for the development, manufacturing, and testing of biopharmaceutical products. Biologics, which include complex drugs derived from living cells or organisms, are a key focus. These organizations assist biopharmaceutical companies in various stages of drug development by providing expertise in process development, analytical testing, and regulatory compliance.
Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Dynamics
Drivers
- Increasing Demand for Biologics
The pharmaceutical industry is experiencing a surge in demand for biologics due to their efficacy in treating complex diseases. Biologics CDMOs are essential in meeting this demand, offering specialized expertise in the intricate production processes required for these advanced therapeutic products. As biologics become a cornerstone of modern medicine, the collaborative efforts between pharmaceutical companies and biologics CDMOs contribute to addressing patient needs and expanding treatment options.
- Cost-Efficiency and Flexibility
Biologics CDMOs provide a cost-effective solution for drug developers by offering access to established facilities, equipment, and skilled personnel. Outsourcing to these organizations allows companies to avoid substantial upfront capital investments, reducing overall development costs. Additionally, the flexibility offered by Biologics CDMOs enables companies to adapt production capacities quickly, responding to market fluctuations and ensuring efficient resource utilization in the rapidly evolving biopharmaceutical landscape.
Opportunities
- Advanced Therapies and Personalized Medicine
With the rise of gene and cell therapies, CDMOs specializing in these advanced therapies stand to benefit. These therapies often require highly specialized manufacturing processes, and CDMOs that can navigate the complexities of production, quality control, and scalability may capture a growing market share.
- Digitalization of the industry
The integration of digital technologies, artificial intelligence, and automation into biologics manufacturing is becoming crucial. CDMOs embracing Industry 4.0 concepts can enhance efficiency, reduce costs, and ensure the quality of biologic products. The implementation of data analytics in real-time monitoring and decision-making processes may position CDMOs as leaders in the evolving landscape of smart manufacturing for biologics.
Restraints/Challenges
- Complex Manufacturing Processes
The intricate nature of biologics manufacturing, involving living cells and sophisticated purification steps, presents challenges in maintaining consistency and reproducibility. Variability in cell cultures, purification yields, and other factors can impact product quality, requiring advanced process control and monitoring to ensure robust production.
- Regulatory Hurdles
Strict regulatory oversight is inherent in the biologics industry due to the complexity and sensitivity of these therapeutic products. Navigating diverse global regulatory landscapes, staying abreast of evolving guidelines, and ensuring compliance with quality standards demand substantial investments in documentation, validation, and adherence to good manufacturing practices (GMP). Any regulatory missteps can result in delays and increased costs, underscoring the importance of meticulous regulatory strategies for CDMOs.
This biologics contract development and manufacturing organization (CDMO) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biologics contract development and manufacturing organization (CDMO) Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Scope
The biologics contract development and manufacturing organization (CDMO) market is segmented based on the basis of surgery, product, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Gene products
- Vaccines
- Stem Cells
- Monoclonal Antibodies
- Others
Service Type
- Manufacturing
- Research and Development
- Clinical Trials
- Others
End-Users
- Biotechnology Companies
- Biopharmaceutical Companies
- Others
Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Regional Analysis/Insights
The biologics contract development and manufacturing organization (CDMO) Market is analyzed and market size insights and trends are provided by d by country, product, type, service type, and end-users as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and rest of Middle East and Africa.
North America is expected to dominate the market due to higher production rates of biological drugs.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period due to the rising research and development activities of pharmaceutical and biotechnological companies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The biologics contract development and manufacturing organization (CDMO) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for biologics contract development and manufacturing organization (CDMO) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the biologics contract development and manufacturing organization (CDMO) market. The data is available for historic period 2010-2020.
Competitive Landscape and Biologics Contract Development and Manufacturing Organization (CDMO) Market Share Analysis
The biologics contract development and manufacturing organization (CDMO) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biologics contract development and manufacturing organization (CDMO) market.
Some of the major players operating in the biologics contract development and manufacturing organization (CDMO) market are:
- Boehringer Ingelheim Group (Germany)
- Wuxi Biologics (China)
- Samsung Biologics (South Korea)
- Lonza Group (Switzerland)
- Fujifilm Diosynth Biotechnologies USA Inc. (U.S.)
- Toyobo Co. Limited (Japan)
- Parexel International Corporation (U.S.)
- Icon PLC (Ireland)
- Binex Co. Limited (South Korea)
- JRS Pharma (Germany)
- Rentschler Biotechnologies (Germany)
- AGC Biologics (U.S.)
- Catalent Inc. (U.S.)
SKU-